We have some exciting news for anal cancer thrivers and their loved ones: last month, for the first time in decades, therapeutic options for metastatic HPV-related cancers leapt forward.
Results from a study out of MD Anderson showed that metastatic anal cancer patients had an enormous response rate (24%) to a new immunotherapy compound. Further, the drug was well tolerated with minimal side effects.The research was published in the Lancet, one of the most renown medical journals in the world.Immunotherapies are showing great promise.
With 4 new immunotherapies in the research pipeline, and the first anal cancer cell line in development, treatment for anal cancer is finally advancing past the standards set in the 1970s.The next set of studies will be look at combining the new compound with additional immunotherapy drugs and other chemotherapy agents to strengthen interactions.
If you feel as though you may be a good candidate for these trials please contact us for an introduction to the research teams. Otherwise, sign up for our newsletter to stay up to date on these exciting achievements and be a part of making history.
Thank you for being a part of this journey with us.
Justine, Tristan and Camille